-
Something wrong with this record ?
A composite device for viscosupplementation treatment resistant to degradation by reactive oxygen species and hyaluronidase
E. Toropitsyn, M. Pravda, D. Rebenda, I. Ščigalková, M. Vrbka, V. Velebný
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
35727166
DOI
10.1002/jbm.b.35114
Knihovny.cz E-resources
- MeSH
- Osteoarthritis, Knee * MeSH
- Chondroitin Sulfates pharmacology MeSH
- Hyaluronoglucosaminidase therapeutic use MeSH
- Injections, Intra-Articular MeSH
- Hyaluronic Acid pharmacology MeSH
- Humans MeSH
- Osteoarthritis * drug therapy MeSH
- Reactive Oxygen Species MeSH
- Tyramine therapeutic use MeSH
- Viscosupplementation * methods MeSH
- Viscosupplements therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Osteoarthritis (OA) is one of the most common musculoskeletal disorders in the world. OA is often associated with the loss of viscoelastic and tribological properties of synovial fluid (SF) due to degradation of hyaluronic acid (HA) by reactive oxygen species (ROS) and hyaluronidases. Viscosupplementation is one of the ways how to effectively restore SF functions. However, current viscosupplementation products provide only temporal therapeutic effect because of short biological half-life. In this article we describe a novel device for viscosupplementation (NV) based on the cross-linked tyramine derivative of HA, chondroitin sulfate (CS), and high molecular weight HA by online determination of viscoelastic properties loss during degradation by ROS and hyaluronidase. Rheological and tribological properties of developed viscosupplement were compared with HA solutions with different molecular weights in the range 500-2000 kDa, which are currently commonly used as medical devices for viscosupplementation treatment. Moreover, based on clinical practice and scientific literature all samples were also diluted by model OA SF in the ratio 1:1 (vol/vol) to better predict final properties after injection to the joint. The observed results confirmed that NV exhibits appropriate rheological properties (viscosity, elastic, and viscous moduli) comparable with healthy SF and maintain them during degradation for a significantly longer time than HA solutions with molecular weight in the range 500-2000 kDa and cross-linked material without CS.
Biocev 1st Faculty of Medicine Charles University Vestec Czech Republic
Contipro a s Dolní Dobrouč Czech Republic
Faculty of Mechanical Engineering Brno University of Technology Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032502
- 003
- CZ-PrNML
- 005
- 20230131151244.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/jbm.b.35114 $2 doi
- 035 __
- $a (PubMed)35727166
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Toropitsyn, Evgeniy $u Contipro a.s., Dolní Dobrouč, Czech Republic $u Biocev, First Faculty of Medicine Charles University, Vestec, Czech Republic $1 https://orcid.org/0000000322031150
- 245 12
- $a A composite device for viscosupplementation treatment resistant to degradation by reactive oxygen species and hyaluronidase / $c E. Toropitsyn, M. Pravda, D. Rebenda, I. Ščigalková, M. Vrbka, V. Velebný
- 520 9_
- $a Osteoarthritis (OA) is one of the most common musculoskeletal disorders in the world. OA is often associated with the loss of viscoelastic and tribological properties of synovial fluid (SF) due to degradation of hyaluronic acid (HA) by reactive oxygen species (ROS) and hyaluronidases. Viscosupplementation is one of the ways how to effectively restore SF functions. However, current viscosupplementation products provide only temporal therapeutic effect because of short biological half-life. In this article we describe a novel device for viscosupplementation (NV) based on the cross-linked tyramine derivative of HA, chondroitin sulfate (CS), and high molecular weight HA by online determination of viscoelastic properties loss during degradation by ROS and hyaluronidase. Rheological and tribological properties of developed viscosupplement were compared with HA solutions with different molecular weights in the range 500-2000 kDa, which are currently commonly used as medical devices for viscosupplementation treatment. Moreover, based on clinical practice and scientific literature all samples were also diluted by model OA SF in the ratio 1:1 (vol/vol) to better predict final properties after injection to the joint. The observed results confirmed that NV exhibits appropriate rheological properties (viscosity, elastic, and viscous moduli) comparable with healthy SF and maintain them during degradation for a significantly longer time than HA solutions with molecular weight in the range 500-2000 kDa and cross-linked material without CS.
- 650 _2
- $a chondroitinsulfáty $x farmakologie $7 D002809
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kyselina hyaluronová $x farmakologie $7 D006820
- 650 _2
- $a hyaluronoglukosaminidasa $x terapeutické užití $7 D006821
- 650 _2
- $a injekce intraartikulární $7 D007270
- 650 12
- $a osteoartróza $x farmakoterapie $7 D010003
- 650 12
- $a artróza kolenních kloubů $7 D020370
- 650 _2
- $a reaktivní formy kyslíku $7 D017382
- 650 _2
- $a tyramin $x terapeutické užití $7 D014439
- 650 12
- $a viskosuplementace $x metody $7 D055676
- 650 _2
- $a viskosuplementy $x terapeutické užití $7 D055675
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pravda, Martin $u Contipro a.s., Dolní Dobrouč, Czech Republic
- 700 1_
- $a Rebenda, David $u Faculty of Mechanical Engineering, Brno University of Technology, Brno, Czech Republic
- 700 1_
- $a Ščigalková, Ivana $u Contipro a.s., Dolní Dobrouč, Czech Republic
- 700 1_
- $a Vrbka, Martin $u Faculty of Mechanical Engineering, Brno University of Technology, Brno, Czech Republic
- 700 1_
- $a Velebný, Vladimír $u Contipro a.s., Dolní Dobrouč, Czech Republic
- 773 0_
- $w MED00007497 $t Journal of biomedical materials research. Part B, Applied biomaterials $x 1552-4981 $g Roč. 110, č. 12 (2022), s. 2595-2611
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35727166 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151240 $b ABA008
- 999 __
- $a ok $b bmc $g 1891327 $s 1183837
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 110 $c 12 $d 2595-2611 $e 20220621 $i 1552-4981 $m Journal of biomedical materials research. Part B, Applied biomaterials $n J Biomed Mater Res $x MED00007497
- LZP __
- $a Pubmed-20230120